nach oben

Digestive Diseases and Sciences

Erschienen in:

01.05.2014 | Original Article

Dysregulation of MicroRNA-34a Expression in Colorectal Cancer Inhibits the Phosphorylation of FAK Via VEGF

verfasst von: Danhua Zhang, Jianping Zhou, Ming Dong

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

MicroRNAs (miRs) are small non-coding RNAs that play important roles in cancer development where they can act as oncogenes or as tumor-suppressors. MiR-34a is a tumor suppressor that is frequently downregulated in a number of tumor types. However, little is known about the role of miR-34a in colorectal cancer (CRC).

Aim

This study aims to show the dysregulation of miR-34a in CRC and to characterize the function and mechanism of miR-34a in CRC cell lines.

Methods

The expression of miR-34a was detected using real-time PCR on CRC tissues and adjacent non-tumorous tissues. The ELISA was used to assess vascular endothelial growth factor (VEGF). The focal adhesion kinase (FAK) and phosphorylated FAK Y397 (pY397FAK) were measured by Western blot. The functions of miR-34a in vivo were measured by migration, invasion, CCK-8 assay and flow cytometry.

Results

MiR-34a was significantly downregulated and pY397FAK was upregulated in CRC cancer tissues. It plays an important role in inhibiting migration and invasion and in increasing apoptosis of CRC cells. Bioinformatic analysis suggested that VEGF may be a target of miR-34a, and this hypothesis was proved by ELISA and RT-PCR. The level of pY397FAK that could be activated by VEGF was downregulated in miR-34a overexpression CRC cell lines. The phosphorylation of FAK at 397 sites in miR-34a-stable cell lines was completely rescued by extra VEGF treatment.

Conclusion

MiR-34a is frequently downregulated in CRC and modulates the phosphorylation of FAK by negatively regulating VEGF.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedCrossRef

Pellegrino L, Jacob J, Roca-Alonso L, Krell J, Castellano L, et al. Altered expression of the miRNA processing endoribonuclease Dicer has prognostic significance in human cancers. Expert Rev Anticancer Ther. 2013;13:21–27.PubMedCrossRef

Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–289.PubMedCrossRef

Akbari Moqadam F, Pieters R, den Boer ML. The hunting of targets: challenge in miRNA research. Leukemia. 2013;27:16–23.PubMedCrossRef

Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013;32:4806–4813.

Takahashi M, Sung B, Shen Y, Hur K, Link A, et al. Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis. 2012;33:2441–2449.PubMedCentralPubMedCrossRef

de Krijger I, Mekenkamp LJ, Punt CJ, Nagtegaal ID. MicroRNAs in colorectal cancer metastasis. J Pathol. 2011;224:438–447.PubMedCrossRef

Stratmann J, Wang CJ, Gnosa S, Wallin A, Hinselwood D, et al. Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients. BMC Cancer. 2011;11:345.PubMedCentralPubMedCrossRef

Bensen JT, Tse CK, Nyante SJ, Barnholtz-Sloan JS, Cole SR, et al. Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes Control. 2013;24:1099–1109.

10.

Bandi N, Vassella E. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011;10:55.PubMedCentralPubMedCrossRef

11.

Xu X, Fan Z, Kang L, Han J, Jiang C, et al. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest. 2013;123:630–645.

12.

Yue X, Wang P, Xu J, Zhu Y, Sun G, et al. MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncol Rep. 2012;27:1200–1206.PubMedCentralPubMed

13.

Volkomorov V, Grigoryeva E, Krasnov G, Litviakov N, Tsyganov M, et al. Search for potential gastric cancer markers using miRNA databases and gene expression analysis. Exp Oncol. 2013;35:2–7.PubMed

14.

Ji X, Wang Z, Geamanu A, Goja A, Sarkar FH, et al. Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int J Cancer. 2012;131:2668–2677.PubMedCrossRef

15.

Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008;377:114–119.PubMedCrossRef

16.

Duan W, Xu Y, Dong Y, Cao L, Tong J, et al. Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. J Radiat Res. 2013;54:611–619.

17.

Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–752.PubMedCentralPubMedCrossRef

18.

Zhao H, Ma B, Wang Y, Han T, Zheng L, et al. miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. Oncol Rep. 2013;29:1027–1036.PubMed

19.

Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 2011;130:663–679.PubMedCentralPubMedCrossRef

20.

Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903–1909.PubMedCrossRef

21.

Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One. 2011;6:e24099.PubMedCentralPubMedCrossRef

22.

Roy S, Levi E, Majumdar AP, Sarkar FH. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 2012;5:58.PubMedCentralPubMedCrossRef

23.

Cho SG, Yi Z, Pang X, Yi T, Wang Y, et al. Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res. 2009;69:7062–7070.PubMedCentralPubMedCrossRef

24.

Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, et al. VEGF-induced vascular permeability is mediated by FAK. Dev Cell. 2012;22:146–157.PubMedCentralPubMedCrossRef

25.

Schlaepfer DD, Hunter T. Signal transduction from the extracellular matrix—a role for the focal adhesion protein–tyrosine kinase FAK. Cell Struct Funct. 1996;21:445–450.PubMedCrossRef

26.

Pang X, Zhang L, Lai L, Chen J, Wu Y, et al. 1′-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway. Carcinogenesis. 2011;32:904–912.PubMedCentralPubMedCrossRef

27.

He K, Cui B, Li G, et al. The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther. 2012;5:59–65.PubMedCentralPubMed

28.

Sun F, Fu H, Liu Q, Tie Y, Zhu J, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008;582:1564–1568.PubMedCrossRef

29.

Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S, et al. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood. 2009;114:404–414.PubMedCentralPubMedCrossRef

30.

Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, et al. TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303.PubMedCentralPubMedCrossRef

31.

Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, et al. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene. 2011;30:2888–2899.PubMedCrossRef

32.

Gilmore AP, Romer LH. Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell. 1996;7:1209–1224.PubMedCentralPubMedCrossRef

Titel: Dysregulation of MicroRNA-34a Expression in Colorectal Cancer Inhibits the Phosphorylation of FAK Via VEGF
verfasst von: Danhua Zhang
Jianping Zhou
Ming Dong
Publikationsdatum: 01.05.2014
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 5/2014
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-013-2983-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aim

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

Improved Post-Transplant Survival in the United States for Patients with Cholangiocarcinoma After 2000

SEDASYS®, Airway, Oxygenation, and Ventilation: Anticipating and Managing the Challenges

Reverse-Phase Protein Array Analysis to Identify Biomarker Proteins in Human Pancreatic Cancer

BVES Inhibition Triggers Epithelial-Mesenchymal Transition in Human Hepatocellular Carcinoma

Is l-Glutathione More Effective Than l-Glutamine in Preventing Enteric Diabetic Neuropathy?